Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis

References

• Li HN, Li XR, Lv ZT, et al. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status. Cancer Med. 2020;9(24):9554–9570.
   PubMed Web of Science ®Google Scholar
• Corbeau I, Thezenas S. Inflammatory blood markers as prognostic and predictive factors in early breast cancer patients receiving neoadjuvant chemotherapy. Cancers. 2020;12(9):2666.
   PubMed Web of Science ®Google Scholar
• Katayama H, Tsou P, Kobayashi M, et al. A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer. NPJ Precis Oncol. 2019;3:10.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou Y, Ma X, et al. Inhibition lysosomal degradation of clusterin by protein kinase D3 promotes triple-negative breast cancer tumor growth. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 2021;8(4):2003205.
   PubMedGoogle Scholar
• You F, Li J, Zhang P, et al. miR106a promotes the growth of transplanted breast cancer and decreases the sensitivity of transplanted tumors to cisplatin. Cancer Manage Res. 2020;12:233–246.
   PubMed Web of Science ®Google Scholar
• Subramani R, Estrada A, Dixon M, et al. Pregnancy inhibits mammary carcinogenesis by persistently altering the hypothalamic-pituitary axis. Cancers. 2021;13(13):3207.
   PubMed Web of Science ®Google Scholar
• Qian C, Chen S, Li S, et al. Circ_0000003 regulates glutamine metabolism and tumor progression of tongue squamous cell carcinoma via the miR‑330‑3p/GLS axis. Oncol Rep. 2021;45(4). DOI:10.3892/or.2021.7996
   Web of Science ®Google Scholar
• Lei M, Zheng G, Ning Q, et al. Translation and functional roles of circular RNAs in human cancer. Mol Cancer. 2020;19(1):30.
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Liang Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduction and Targeted Therapy. 2020;5(1):298.
   PubMed Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149.
   PubMed Web of Science ®Google Scholar
• Huang X, Li Z, Zhang Q, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Molecular Cancer. 2019;18(1):71.
   PubMed Web of Science ®Google Scholar
• Dai J, Zhuang Y, Tang M, et al. CircRNA UBAP2 facilitates the progression of colorectal cancer by regulating miR-199a/VEGFA pathway. Eur Rev Med Pharmacol Sci. 2020;24(15):7963–7971.
   PubMed Web of Science ®Google Scholar
• Xiong H, Yu J, Jia G, et al. Emerging roles of circUBAP2 targeting miR-370-3p in proliferation, apoptosis, and invasion of papillary thyroid cancer cells. Hum Cell. 2021;34(6):1866–1877.
   PubMed Web of Science ®Google Scholar
• Ma W, Xue N, Zhang J, et al. circUBAP2 regulates osteosarcoma progression via the miR‑204‑3p/HMGA2 axis. Int J Oncol. 2021;58(3):298–311.
   PubMed Web of Science ®Google Scholar
• Wang S, Li Q, Wang Y, et al. Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway. Biochem Biophysical Res Commun. 2018;505(4):996–1002.
   PubMed Web of Science ®Google Scholar
• He W, Shi X, Guo Z, et al. Circ_0019693 promotes osteogenic differentiation of bone marrow mesenchymal stem cell and enhances osteogenesis-coupled angiogenesis via regulating microRNA-942-5p-targeted purkinje cell protein 4 in the development of osteoporosis. Bioengineered. 2022;13(2):2181–2193.
   PubMed Web of Science ®Google Scholar
• Xu L, Tan Y, Xu F, et al. Long noncoding RNA ADIRF antisense RNA 1 upregulates insulin receptor substrate 1 to decrease the aggressiveness of osteosarcoma by sponging microRNA-761. Bioengineered. 2022;13(2):2028–2043.
   PubMed Web of Science ®Google Scholar
• Xie F, Xiong Y, Yan J, et al. Circular RNA circ_0048764 promotes the development of breast cancer by regulating microRNA-1296-5p/tripartite motif containing 14 axis. Bioengineered. 2022;13(2):1963–1974.
   PubMed Web of Science ®Google Scholar
• Liu B, Tian Y, Chen M, et al. CircUBAP2 promotes MMP9-mediated oncogenic effect via sponging miR-194-3p in hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:675043.
   PubMed Web of Science ®Google Scholar
• Chen F, Guo L, and Di J, et al., Circular RNA ubiquitin-associated protein 2 enhances autophagy and promotes colorectal cancer progression and metastasis via miR-582-5p/FOXO1 signaling. Yi chuan xue bao. 2021;48(12):1091-1103 .
   Google Scholar
• Qi T, Zhang D, Shi X, et al. Decreased circUBAP2 expression is associated with preeclampsia by limiting trophoblast cell proliferation and migration. Reproductive Sciences (Thousand Oaks, Calif.). 2021;28(8):2237–2245.
   PubMed Web of Science ®Google Scholar
• Fan S, Yan S, Yang Y, et al. Actin-like protein 8 promotes the progression of triple-negative breast cancer via activating PI3K/AKT/mTOR pathway. Oncol Targets Ther. 2021;14:2463–2473.
   PubMed Web of Science ®Google Scholar
• Hu H, Zhu J, Zhong Y, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med. 2021;9(5):410.
   PubMed Web of Science ®Google Scholar
• Lopes N, Correia VG. Cracking the breast cancer glyco-code through glycan-lectin interactions: targeting immunosuppressive macrophages. Int J Mol Sci. 2021;22(4):1972.
   PubMed Web of Science ®Google Scholar
• Liu XY, Jiang W, Ma D, et al. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer. Theranostics. 2020;10(24):10940–10956.
   PubMed Web of Science ®Google Scholar
• Lee KM, Giltnane JM, Balko JM, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabol. 2017;26(4):633–647.e637.
   PubMed Web of Science ®Google Scholar
• Haga Y, Higashisaka K, Yang L, et al. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer. Biochem Biophysical Res Commun. 2020;533(4):672–678.
   PubMed Web of Science ®Google Scholar
• Liang M, Yao W, Shi B. Circular RNA hsa_circ_0110389 promotes gastric cancer progression through upregulating SORT1 via sponging miR-127-5p and miR-136-5p. Cell Death & Disease. 2021;12(7):639.
   PubMed Web of Science ®Google Scholar
• Yu T, Wang Y, Fan Y, et al. CircRNAs in cancer metabolism: a review. Journal of Hematology & Oncology. 2019;12(1):90.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao X, Wang Y, et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11(1):32.
   PubMed Web of Science ®Google Scholar
• Sang Y, Chen B, Song X, et al. circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther. 2019;27(9):1638–1652.
   PubMed Web of Science ®Google Scholar
• Guan Y, Zhang Y, Hao L, et al. CircRNA_102272 promotes cisplatin-resistance in hepatocellular carcinoma by decreasing miR-326 targeting of RUNX2. Cancer Manage Res. 2020;12:12527–12534.
   PubMed Web of Science ®Google Scholar
• Ge W, Han C, Wang J, et al. MiR-300 suppresses laryngeal squamous cell carcinoma proliferation and metastasis by targeting ROS1. Am J Transl Res. 2016;8(9):3903–3911.
   PubMed Web of Science ®Google Scholar
• Chang Y, Zhou C, Fan L, et al. Upregulation of microRNA‑300 induces the proliferation of liver cancer by downregulating transcription factor FOXO1. Oncol Rep. 2018;40(6):3561–3572.
   PubMed Web of Science ®Google Scholar
• Kang Y, Zhang Y, Sun Y, et al. MicroRNA-300 suppresses metastasis of oral squamous cell carcinoma by inhibiting epithelial-to-mesenchymal transition. Oncol Targets Ther. 2018;11:5657–5666.
   PubMed Web of Science ®Google Scholar
• Zhang W, Gao Z, Guan M, et al. ASF1B promotes oncogenesis in lung adenocarcinoma and other cancer types. Front Oncol. 2021;11:731547.
   PubMedGoogle Scholar
• Mbianda J, Bakail M, André C. Optimal anchoring of a foldamer inhibitor of ASF1 histone chaperone through backbone plasticity. Science Advances. 2021;7(12). DOI:10.1126/sciadv.abd9153
   PubMed Web of Science ®Google Scholar
• Hu X, Zhu H, Zhang X, et al. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker. Cancer Medicine. 2021;10(19):6897–6916.
   PubMed Web of Science ®Google Scholar
• Liu X, Song J, Zhang Y, et al. ASF1B promotes cervical cancer progression through stabilization of CDK9. Cell Death & Disease. 2020;11(8):705.
   PubMed Web of Science ®Google Scholar
• Jiangqiao Z, Tao Q, Zhongbao C, et al. Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma. Biochem Biophysical Res Commun. 2019;511(1):165–172.
   PubMed Web of Science ®Google Scholar
• Han G, Zhang X, Liu P, et al. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer. Int J Oncol. 2018;53(5):2056–2066.
   PubMed Web of Science ®Google Scholar
• Corpet A, De Koning L, Toedling J, et al. Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J. 2011;30(3):480–493.
   PubMed Web of Science ®Google Scholar
• Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–160.
   PubMed Web of Science ®Google Scholar
• Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(3):511–518.
   PubMed Web of Science ®Google Scholar
• Shorning BY, Dass MS, Smalley MJ. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. International Journal of Molecular Sciences. 2020;21(12). DOI:10.3390/ijms21124507
   PubMed Web of Science ®Google Scholar
• Li D, Ji H, Niu X, et al. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Science. 2020;111(1):47–58.
   PubMed Web of Science ®Google Scholar
• Zong S, Dai W, Fang W, et al. SIK2 promotes cisplatin resistance induced by aerobic glycolysis in breast cancer cells through PI3K/AKT/mTOR signaling pathway. Biosci Rep. 2020. DOI:10.1042/BSR20201302
   Google Scholar
• Zhang J, Xie T. Ghrelin inhibits cisplatin-induced MDA-MB-231 breast cancer cell apoptosis via PI3K/Akt/mTOR signaling. Exp Therap Med. 2020;19(3):1633–1640.
   PubMed Web of Science ®Google Scholar
• Costa RLB, Han HS, Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018;169(3):397–406.
   PubMed Web of Science ®Google Scholar
• Khan MA, Jain VK, Rizwanullah M, et al. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019;24(11):2181–2191.
   PubMed Web of Science ®Google Scholar
• Wu C, Qiu S, Liu P, et al. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway. J Ethnopharmacol. 2018;211:89–100.
   PubMed Web of Science ®Google Scholar